Article info
PDFHow to do it
First-line immunosuppression in neuromuscular diseases
- Correspondence to Dr Michael A Foster, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, WC1E 6BT, UK; m.a.foster{at}ucl.ac.uk
Citation
First-line immunosuppression in neuromuscular diseases
Publication history
- Accepted March 29, 2023
- First published May 12, 2023.
Online issue publication
July 28, 2023
Article Versions
- Previous version (12 May 2023).
- You are viewing the most recent version of this article.
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Intractable chronic inflammatory demyelinating polyneuropathy treated successfully with ciclosporin
- A nationwide survey of combined central and peripheral demyelination in Japan
- Diagnostic value of sural nerve biopsy in chronic inflammatory demyelinating polyneuropathy
- Chronic inflammatory demyelinating polyneuropathy associated with diabetes: a European multicentre comparative reappraisal
- Long term prognosis of chronic inflammatory demyelinating polyneuropathy: a five year follow up of 38 cases
- Iatrogenic immune-mediated neuropathies: diagnostic, epidemiological and mechanistic uncertainties for causality and implications for clinical practice
- Autologous haematopoietic stem cell transplantation: a viable treatment option for CIDP
- Treatment of CIDP
- Chronic inflammatory demyelinating polyneuropathy and pregnancy: systematic review
- Validity of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy: a multicentre European study